Guardant Health received FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to support treatment selection in advanced cancer. The company said the new assay analyzes a 100-fold larger genomic footprint than the previously approved Guardant360 CDx. Guardant said the upgrade expands sensitivity for circulating tumor DNA and that the seven companion diagnostic indications already granted for earlier Guardant360 versions will carry over to the new test. The approval also positions Guardant360 Liquid CDx as the broader “next generation” CDx tool for oncology decision-making. The move is likely to accelerate payer and clinical adoption where liquid biopsy is used as a practical substitute for tissue, particularly when sample availability or timing limits trial enrollment or treatment planning.